JP7359973B2 - エクオールの経口による血中吸収性を向上させる方法及びβ－シクロデキストリンからなるエクオールの血中吸収促進剤 - Google Patents

エクオールの経口による血中吸収性を向上させる方法及びβ－シクロデキストリンからなるエクオールの血中吸収促進剤 Download PDF

Info

Publication number
JP7359973B2
JP7359973B2 JP2022571676A JP2022571676A JP7359973B2 JP 7359973 B2 JP7359973 B2 JP 7359973B2 JP 2022571676 A JP2022571676 A JP 2022571676A JP 2022571676 A JP2022571676 A JP 2022571676A JP 7359973 B2 JP7359973 B2 JP 7359973B2
Authority
JP
Japan
Prior art keywords
equol
cyclodextrin
clathrate
microorganisms
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022571676A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022138909A1 (cg-RX-API-DMAC10.html
JPWO2022138909A5 (cg-RX-API-DMAC10.html
Inventor
素子 林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daicel Corp
Original Assignee
Daicel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daicel Corp filed Critical Daicel Corp
Publication of JPWO2022138909A1 publication Critical patent/JPWO2022138909A1/ja
Publication of JPWO2022138909A5 publication Critical patent/JPWO2022138909A5/ja
Priority to JP2023166660A priority Critical patent/JP7432053B2/ja
Application granted granted Critical
Publication of JP7359973B2 publication Critical patent/JP7359973B2/ja
Priority to JP2024014953A priority patent/JP7484030B2/ja
Priority to JP2024074490A priority patent/JP2024097852A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
JP2022571676A 2020-12-24 2021-12-24 エクオールの経口による血中吸収性を向上させる方法及びβ－シクロデキストリンからなるエクオールの血中吸収促進剤 Active JP7359973B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023166660A JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法
JP2024074490A JP2024097852A (ja) 2020-12-24 2024-05-01 シクロデキストリンにエクオールが包接された包接体の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020215247 2020-12-24
JP2020215247 2020-12-24
PCT/JP2021/048167 WO2022138909A1 (ja) 2020-12-24 2021-12-24 シクロデキストリンにエクオールが包接された包接体、該包接体を含有するエクオール吸収性組成物、及びこれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023166660A Division JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物

Publications (3)

Publication Number Publication Date
JPWO2022138909A1 JPWO2022138909A1 (cg-RX-API-DMAC10.html) 2022-06-30
JPWO2022138909A5 JPWO2022138909A5 (cg-RX-API-DMAC10.html) 2023-08-18
JP7359973B2 true JP7359973B2 (ja) 2023-10-11

Family

ID=82158029

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022571676A Active JP7359973B2 (ja) 2020-12-24 2021-12-24 エクオールの経口による血中吸収性を向上させる方法及びβ－シクロデキストリンからなるエクオールの血中吸収促進剤
JP2023166660A Active JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A Active JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法
JP2024074490A Pending JP2024097852A (ja) 2020-12-24 2024-05-01 シクロデキストリンにエクオールが包接された包接体の製造方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023166660A Active JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A Active JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法
JP2024074490A Pending JP2024097852A (ja) 2020-12-24 2024-05-01 シクロデキストリンにエクオールが包接された包接体の製造方法

Country Status (3)

Country Link
US (1) US20240082424A1 (cg-RX-API-DMAC10.html)
JP (4) JP7359973B2 (cg-RX-API-DMAC10.html)
WO (1) WO2022138909A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025070550A1 (ja) 2023-09-27 2025-04-03 Ｓｂカワスミ株式会社 バルーン付きガイドワイヤ、カテーテルセットおよび医療用機器

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012135218A (ja) 2010-12-24 2012-07-19 Daicel Corp エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品
WO2013058303A1 (ja) 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
JP2020058319A (ja) 2018-10-12 2020-04-16 株式会社ダイセル ６−ヒドロキシダイゼインの製造方法
JP2020092690A (ja) 2018-12-07 2020-06-18 学校法人東京理科大学 エクオール誘導体の産生のための組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272260A1 (en) * 2002-09-09 2004-03-29 Josef Pitha Verifiable absorption drug delivery form based on cyclodextrins
SI2548455T1 (sl) * 2003-06-30 2016-11-30 Otsuka Pharmaceutical Co., Ltd. Sestavek, ki vsebuje mlečno kislinsko bakterijo, ki proizvaja ekvol
JP2006111534A (ja) 2004-10-12 2006-04-27 Bio Taxol:Kk クルクミン水溶液の製造方法
WO2007066655A1 (ja) 2005-12-06 2007-06-14 Otsuka Pharmaceutical Co., Ltd. エクオール含有大豆胚軸発酵物、及びその製造方法
JP2008061584A (ja) * 2006-09-08 2008-03-21 Asano Kozo エクオール生産能を持つ微生物及び飲食品、医薬品、動物飼料およびその製造法
JPWO2008126752A1 (ja) * 2007-04-09 2010-07-22 株式会社林原生物化学研究所 エクオール類を有効成分とする美白剤
TW201444815A (zh) 2007-06-13 2014-12-01 大塚製藥股份有限公司 含雌馬酚（ｅｑｕｏｌ）之萃取物、其製造方法、雌馬酚萃取方法及含雌馬酚之食品（二）
JP5916132B2 (ja) * 2010-09-08 2016-05-11 株式会社ダイセル エクオールの製造方法
JP5851685B2 (ja) * 2010-12-24 2016-02-03 株式会社ダイセル エクオールの製造方法、エクオール産生組成物、食品、食品添加物及び医薬品
JP6005453B2 (ja) * 2012-09-14 2016-10-12 株式会社ダイセル オルニチンとエクオールを含む組成物
JP6132398B2 (ja) * 2013-06-04 2017-05-24 株式会社ダイセル エクオール以外のイソフラボン類の含有量が低いエクオール含有組成物
JP2015139424A (ja) * 2014-01-30 2015-08-03 株式会社ダイセル エクオール含有組成物の製造方法
EP3191464B1 (en) * 2014-09-10 2019-11-06 System Biologie AG Synthesis of isoflavanes and intermediates thereof
JP2019011370A (ja) * 2018-10-24 2019-01-24 株式会社ダイセル エクオール含有組成物の製造方法
JP6931747B2 (ja) 2018-10-30 2021-09-08 太陽化学株式会社 容器詰飲料
JP7451185B2 (ja) 2019-01-22 2024-03-18 株式会社ダイセル 新規微生物およびその利用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012135218A (ja) 2010-12-24 2012-07-19 Daicel Corp エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品
WO2013058303A1 (ja) 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
JP2020058319A (ja) 2018-10-12 2020-04-16 株式会社ダイセル ６−ヒドロキシダイゼインの製造方法
JP2020092690A (ja) 2018-12-07 2020-06-18 学校法人東京理科大学 エクオール誘導体の産生のための組成物

Also Published As

Publication number Publication date
JPWO2022138909A1 (cg-RX-API-DMAC10.html) 2022-06-30
WO2022138909A1 (ja) 2022-06-30
JP2024036485A (ja) 2024-03-15
JP7484030B2 (ja) 2024-05-15
JP2024097852A (ja) 2024-07-19
US20240082424A1 (en) 2024-03-14
JP2023165927A (ja) 2023-11-17
JP7432053B2 (ja) 2024-02-15

Similar Documents

Publication Publication Date Title
CN1826059B (zh) 含有产生雌马酚的乳酸菌的组合物
CN102159092B (zh) 含有维持了雌马酚产生能力的雌马酚产生微生物的发酵制品及其制备方法
CN1312285C (zh) 制造1,4－二羟基－2萘甲酸的方法
JP7101125B2 (ja) ウロリチン類の製造方法
JP6005453B2 (ja) オルニチンとエクオールを含む組成物
WO2012063826A1 (ja) 高タンパク質分解活性を有するラクトバチルス・ヘルベティカス菌
JP6132398B2 (ja) エクオール以外のイソフラボン類の含有量が低いエクオール含有組成物
JP5851686B2 (ja) エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品
JP7432053B2 (ja) シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP7373402B2 (ja) ウロリチン類の製造方法
JP6371055B2 (ja) イソフラバノン類の製造方法
JP2026012526A (ja) エクオール含有食品組成物およびその製造方法
JP2024010170A (ja) エクオール含有組成物の製造方法
KR20230013255A (ko) 폐경 후에 갱년기 장애를 가지지 않는 만 40세 이상의 여성을 위한 qol 개선용 조성물
JP2024000267A (ja) エクオールの製造方法
JP7743667B1 (ja) 大豆胚軸及び／又は大豆胚軸抽出物の発酵組成物
JP2024097336A (ja) エクオールの製造方法
JP2005323596A (ja) 雲南ｓｌ−００１菌の培養によるビタミンｋの生産方法
JP2018186823A (ja) イソフラバノン類の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230620

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230928

R150 Certificate of patent or registration of utility model

Ref document number: 7359973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150